Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diTyr-DTPA-Gd is a paramagnetic contrast agent designed for enzyme-mediated signal amplification (EMSA) in magnetic resonance imaging (MRI). It consists of a gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) core conjugated to two tyrosine residues. The molecule serves as a substrate for peroxidases, such as horseradish peroxidase (HRP). In the presence of peroxidase and hydrogen peroxide (often generated by glucose oxidase in a dual-enzyme system), diTyr-DTPA-Gd undergoes oxidative polymerization. These polymerized products exhibit higher relaxivity and are retained at the site of enzyme activity (e.g., a tumor targeted by an HRP-conjugated antibody), leading to localized and prolonged T1-weighted MR signal enhancement. It has been primarily investigated in preclinical research for the targeted imaging of EGFRvIII expression in glioblastoma multiforme models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diTyr-DTPA-Gd.